Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.58 |
| ▸ | HEXA | P06865 | 1/20 | 0.58 |
| ▸ | HEXB | P07686 | 1/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15487768 | 0.98 | DHFR (0.56) | DHFRHEXAHEXBCSNK1A1CLK4 | |
| SCHEMBL7162150 | 0.87 | DHFR (0.66) | DHFRHEXAHEXBCSNK1A1CLK4 | |
| SCHEMBL12137698 | 0.84 | ADORA2A (0.60) | DHFRHEXAHEXBCSNK1A1CLK4 | |
| SCHEMBL3118642 | 0.84 | MEN1 (0.54) | DHFRHEXAHEXBCSNK1A1CLK4 | |
| SCHEMBL27612333 | 0.83 | ADORA1 (0.61) | DHFRCSNK1A1CLK4ADORA2AADORA1 | |
| SCHEMBL27631682 | 0.83 | ADORA1 (0.61) | DHFRHEXAHEXBCSNK1A1CLK4 | |
| SCHEMBL16463518 | 0.83 | CSNK1A1 (0.61) | DHFRCSNK1A1CLK4ADORA2AADORA1 | |
| SCHEMBL3117390 | 0.82 | ADORA2A (0.52) | DHFRHEXAHEXBADORA2AADORA1 | |
| SCHEMBL3119208 | 0.82 | ADORA2A (0.52) | DHFRHEXAHEXBADORA2AADORA1 | |
| SCHEMBL1643583 | 0.82 | ADORA2A (0.50) | DHFRHEXAHEXBADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105593215-A | 2, 4-or 4, 6-diaminopyrimidine compounds as IDH2 mutant inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS INC | 2016-05-18 | — | — | CN | claimed |
| CN-112920124-B | Pyrimidine-2, 4-diamine compound, and preparation method and application thereof | 安徽医科大学 | 2024-03-01 | — | — | CN | disclosed |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190016688-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2019-01-17 | — | — | US | disclosed |
| CN-105593215-B | 2, 4-or 4, 6-diaminopyrimidine compounds as IDH2 mutant inhibitors for the treatment of cancer | 安吉奥斯医药品有限公司 | 2019-01-15 | — | — | CN | disclosed |
| US-9597329-B2 | Aurora kinase inhibitors and methods of making and using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9556127-B2 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170000787-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| CN-105593215-A | 2, 4-or 4, 6-diaminopyrimidine compounds as IDH2 mutant inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS INC | 2016-05-18 | — | — | CN | disclosed |
| US-8420659-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Riger Pharmaceuticals, Inc. | 2012-11-29 | — | — | US | disclosed |
| WO-2012135641-A2 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2370415-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010075558-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | DHFR 697/4885HEXA 4366/4885HEXB 4343/4885 |
| US-20190016688-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | DHFR 1126/4885HEXA 1021/4885HEXB 866/4885 |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | DHFR 9/4885HEXA 956/4885HEXB 719/4885 |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | DHFR 697/4885HEXA 4366/4885HEXB 4343/4885 |
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | DHFR 10/4885HEXA 1631/4885HEXB 1016/4885 |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | IDH2, IDH3B, IDH3A | DHFR 9/4885HEXA 956/4885HEXB 719/4885 |
| US-20170000787-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | AURKC, AURKA, AURKB | DHFR 1470/4885HEXA 4105/4885HEXB 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.